Scaling cell production in physiologically relevant High Throughput Screening
| Reference number | |
| Coordinator | Pelago Bioscience AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | October 2024 - September 2025 |
| Status | Ongoing |
| Venture | Utlysning Infrastruktur for the development of accurate drug treatment |
| Call | Use infrastructures to develop precision medicine |
Purpose and goal
Pelago Bioscience aims to demonstrate ‘Scale on demand’ solutions for cell production to significantly reduce the lead time on highly specialized cellular HTS campaigns in commercial drug discovery projects. This study proposes to validate an existing scalable method using rocking bioreactors, for cell line production, ensuring the biological background of bulk unmodified cultured cell lines is consistent from assay development to assay ready cells for HTS in a CETSA screening workflow.
Expected effects and result
The project will establish processes for scaling cell culture of selected cell lines to production volumes of up to 10 billion cells together with processes for cryopreservation and subsequent use in downstream cellular HTS campaigns without compromising biological relevance. The project’s output will be SOPs, QC markers, COGS and delivery times. Upon successful project completion, CETSA HTS campaigns can be run in less time, with less variation and less use of disposable plastics.
Planned approach and implementation
The project will be run in collaboration with the TestaCenter in Uppsala and is divided in 3 work packages. The project lead will initiate a kick-off to agree on objectives, deliverables, timelines and owners. Regular check-ins will be held to keep the team aligned, updated, focused, and able to react to obstacles, and decide on actions for risk mitigation. The project lead will be supported by the sponsor, budget owner (Head of R&D) and the Head of Lab Operations as the receiving department.